Hepatitis Monthly

Published by: Kowsar

Generic Direct Acting Antiviral Treatment: The First Step Towards Elimination of Hepatitis C in Iran

Behzad Hajarizadeh 1 , *
Author Information
1 The Kirby Institute, UNSW Sydney (University of New South Wales), Sydney, Australia
Article information
  • Hepatitis Monthly: January 01, 2017, 17 (1); e45788
  • Published Online: January 22, 2017
  • Article Type: Editorial
  • Received: January 17, 2017
  • Accepted: January 21, 2017
  • DOI: 10.5812/hepatmon.45788

To Cite: Hajarizadeh B. Generic Direct Acting Antiviral Treatment: The First Step Towards Elimination of Hepatitis C in Iran, Hepat Mon. 2017 ; 17(1):e45788. doi: 10.5812/hepatmon.45788.

Copyright © 2017, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
  • 1. Combating hepatitis B and C to reach elimination by 2030. 2016;
  • 2. Hajarizadeh B, Razavi-Shearer D, Merat S, Alavian SM, Malekzadeh R, Razavi H. Liver Disease Burden of Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease Burden. Hepat Mon. 2016; 16(7)[DOI][PubMed]
  • 3. Hajarizadeh B, Grebely J, Martinello M, Matthews GV, Lloyd AR, Dore GJ. Hepatitis C treatment as prevention: evidence, feasibility, and challenges. Lancet Gastroenterol Hepatol. 2016; 1(4): 317-27[DOI]
  • 4. Ford N, Singh K, Cooke GS, Mills EJ, von Schoen-Angerer T, Kamarulzaman A, et al. Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS. Clin Infect Dis. 2012; 54(10): 1465-72[DOI][PubMed]
  • 5. Freeman JA, Hill A. The use of generic medications for hepatitis C. Liver Int. 2016; 36(7): 929-32[DOI][PubMed]
  • 6. Ravinetto R, De Weggheleire A, Dorlo TP, Francque S, Sokkab A, Pouget C, et al. Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpoint. Trop Med Int Health. 2016; 21(12): 1490-5[DOI][PubMed]
  • 7. Sarpel D, Dieterich D. The use of generics to treat chronic hepatitis C: not quite ready for the big stage. Liver Int. 2016; 36(7): 933-5[DOI][PubMed]
  • 8. Merat S, Sharifi AH, Haj-Sheykholeslami A, Poustchi H, Fattahi B, Nateghi-Baygi A, et al. The Efficacy of 12 Weeks of Sofosbuvir, Daclatasvir, and Ribavirin in Treating Hepatitis C Patients with Cirrhosis, Genotypes 1 and 3. Hepat Mon. 2016; 17(1)[DOI]
  • 9. Freeman JA, Sallie R, Kennedy A, Jeffreys G, Savage A, Hill AM. High Sustained Virological Response Rates using Legally Imported, Generic Direct Acting Antiviral Treatment for Hepatitis C. Hepatology. 2016; 63(1 SUPP): 444A
  • 10. Yakoot M, Abdo AM, Yousry A, Helmy S. Very rapid virologic response and early HCV response kinetics, as quick measures to compare efficacy and guide a personalized response-guided therapy. Drug Des Devel Ther. 2016; 10: 2659-67[DOI][PubMed]
  • 11. Hill AM, Golovin S, Dragunova J, Korologou-Linden RS. Virological Response rates using Generic Direct Acting Antiviral Treatment for Hepatitis C, Legally Imported into Russia. Hepatology. 2016; 63(1 SUPP): 1005A
  • 12. Ji D, Chen GF, Wang C, Wang YD, Shao Q, Li B, et al. Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients. Hepatol Int. 2016; 10(5): 789-98[DOI][PubMed]
  • 13. Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016; 63(5): 1493-505[DOI][PubMed]
  • 14. Leroy V, Angus P, Bronowicki JP, Dore GJ, Hezode C, Pianko S, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+). Hepatology. 2016; 63(5): 1430-41[DOI][PubMed]
  • 15. Sahajian F, Bailly F, Vanhems P, Fantino B, Vannier-Nitenberg C, Fabry J, et al. A randomized trial of viral hepatitis prevention among underprivileged people in the Lyon area of France. J Public Health (Oxf). 2011; 33(2): 182-92[DOI][PubMed]
  • 16. Hickman M, McDonald T, Judd A, Nichols T, Hope V, Skidmore S, et al. Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: a cluster randomized controlled trial. J Viral Hepat. 2008; 15(4): 250-4[DOI][PubMed]
  • 17. Grebely J, Alavi M, Micallef M, Dunlop AJ, Balcomb AC, Phung N, et al. Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study. Addiction. 2016; 111(2): 311-9[DOI][PubMed]
  • 18. Grebely J, Knight E, Genoway KA, Viljoen M, Khara M, Elliott D, et al. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol. 2010; 22(3): 270-7[DOI]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments